文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

Claudin-18亚型2特异性CAR T细胞疗法(satri-cel)对比医师选择方案治疗经治晚期胃或胃食管结合部癌(CT041-ST-01):一项随机、开放标签、2期试验

Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial.
PubMed 文献 · Lancet · 2025-05-31

在中国开展的多中心、开放标签、随机对照2期试验纳入156例CLDN18.2阳性经治晚期胃或胃食管结合部癌患者,按2:1随机接受satri-cel或医师选择方案治疗。satri-cel组中位无进展生存期3.25个月,医师选择方案组1.77个月,HR 0.37(95%CI 0.24-0.56),单侧log-rank P<0.0001。

要点

  • satri-cel组中位无进展生存期3.25个月,医师选择方案组1.77个月,HR 0.37。
  • satri-cel组3级及以上治疗中出现的不良事件发生率为87/88(99%),医师选择方案组为30/48(63%)。
  • satri-cel组细胞因子释放综合征发生率为84/88(95%)。

核心结论

  • satri-cel治疗显著改善无进展生存期,安全性可控,结果支持satri-cel作为晚期胃或胃食管结合部癌新的三线治疗。

研究设计与样本

  • 在中国开展的多中心、开放标签、随机对照2期试验,266例患者筛选,156例随机分配至satri-cel组(n=104)或医师选择方案组(n=52)。

主要发现

  • 意向治疗人群中,satri-cel组中位无进展生存期3.25个月(95%CI 2.86-4.53)vs 医师选择方案组1.77个月(95%CI 1.61-2.04),HR 0.37(95%CI 0.24-0.56),单侧log-rank P<0.0001。
  • satri-cel组中位无进展生存期随访时间9.07个月(95%CI 6.21-13.01),医师选择方案组3.45个月(95%CI 2.89-不可估计)。
  • 安全性分析集中,satri-cel组3级及以上治疗中出现的不良事件发生率为87/88(99%),医师选择方案组为30/48(63%)。
  • satri-cel组最常见的3级及以上治疗相关不良事件为淋巴细胞计数降低86/88(98%)、白细胞计数降低68/88(77%)、中性粒细胞计数降低58/88(66%)。
  • satri-cel组细胞因子释放综合征发生率为84/88(95%)。

关键数值与推荐

  • CLDN18.2阳性定义为免疫组化表达强度≥2+且阳性肿瘤细胞≥40%。
  • satri-cel输注剂量为250×10^6个细胞,最多输注3次。
  • 医师选择方案组药物包括纳武利尤单抗、紫杉醇、多西他赛、伊立替康或瑞戈非尼(阿帕替尼)。

临床怎么用

  • 作者认为,satri-cel可作为晚期胃或胃食管结合部癌患者新的三线治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Claudin-18 isoform 2 (CLDN18.2) has emerged as a promising therapeutic target in gastric or gastro-oesophageal junction cancer. Satricabtagene autoleucel (satri-cel; also known as CT041), an autologous CLDN18.2-specific chimeric antigen receptor (CAR) T-cell therapy, showed encouraging activity in previously treated patients with advanced gastric or gastro-oesophageal junction cancer in phase 1 clinical trials. In this Article, we report the primary results from the phase 2 pivotal trial (CT041-ST-01) investigating the efficacy and safety of satri-cel for gastric or gastro-oesophageal junction cancer. METHODS: In this open-label, multicentre, randomised controlled trial conducted in China, patients with CLDN18.2-positive (immunohistochemistry expression intensity ≥2+ and positive tumour cells ≥40%) advanced gastric or gastro-oesophageal junction cancer, who were refractory to at least two previous lines of treatment, were randomly allocated (2:1) to receive satri-cel or treatment of physician's choice (TPC). In the satri-cel group, satri-cel was infused up to three times at a dose of 250 × 106 cells. For the TPC group, one of the standard-of-care drugs (nivolumab, paclitaxel, docetaxel, irinotecan, or rivoceranib [apatinib]) was given, per the physician's decision. Those who had disease progression or drug intolerance in the TPC group could receive subsequent satri-cel, if eligible. The primary endpoint was progression-free survival, assessed by an independent review committee, in the intention-to-treat population. This study is registered with ClinicalTrials.gov (NCT04581473), and is closed to new patients. FINDINGS: Between March 22, 2022, and July 29, 2024, 266 patients were screened, of whom 156 were randomly allocated to the satri-cel group (n=104) or TPC group (n=52). 88 (85%) patients in the satri-cel group and 48 (92%) patients in the TPC group received study drug. In the satri-cel group, 28 (27%) patients had previously received three or more lines of treatment and 72 (69%) patients had peritoneal metastasis. In the TPC group, ten (19%) patients had previously received three or more lines of treatment and 31 (60%) patients had peritoneal metastasis. The median follow-up time for progression-free survival was 9·07 months (95% CI 6·21-13·01) in the satri-cel group and 3·45 months (2·89-not estimable) in the TPC group, based on the reverse Kaplan-Meier method. In the intention-to-treat population, median progression-free survival was 3·25 months (95% CI 2·86-4·53) in the satri-cel group and 1·77 months (1·61-2·04) in the TPC group (hazard ratio 0·37 [95% CI 0·24-0·56]; one-sided log-rank p<0·0001). In the safety analysis set (all patients who received at least one dose of study drug), grade 3 or higher treatment-emergent adverse events occurred in 87 (99%) of 88 patients in the satri-cel group and 30 (63%) of 48 patients in the TPC group. The most common grade 3 or worse treatment-emergent adverse events related to treatment were decreased lymphocyte count (86 [98%] of 88 patients), decreased white blood cell count (68 [77%] patients), and decreased neutrophil count (58 [66%] patients) in the satri-cel group. Cytokine release syndrome occurred in 84 (95%) of 88 patients in the satri-cel group. INTERPRETATION: This is the first randomised controlled trial of CAR T-cell therapy in solid tumours globally. Satri-cel treatment resulted in a significant improvement in progression-free survival, with a manageable safety profile. These results support satri-cel as a new third-line treatment for advanced gastric or gastro-oesophageal junction cancer patients. FUNDING: CARsgen Therapeutics.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Qi C, Liu C, Peng Z, et al. Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial. Lancet. 2025. PMID: 40460847. doi:10.1016/S0140-6736(25)00860-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。